Does Wegovy Affect Eye Pressure? What You Need to Know

What the clinical evidence actually links to semaglutide and the eyes

Wegovy's core side-effect profile is gastrointestinal (nausea, reflux, changes in bowel habit) and these are what most people ask about. Eye pressure specifically has not emerged as a documented effect of semaglutide in the STEP clinical trial programme. The NHS medicines page for semaglutide does not list raised intraocular pressure among the known side effects, and no regulatory warning has been issued on that basis.

What has drawn attention is something different: a condition called non-arteritic anterior ischaemic optic neuropathy (NAION), a form of optic nerve damage that causes sudden vision loss, typically without pain. An observational study published in 2024 reported a higher rate of NAION diagnoses among people taking semaglutide compared with those on other treatments, a finding significant enough that it is being investigated, though causality has not been established. Observational data shows association, not cause, and the absolute numbers involved remain small. Still, it is real enough that anyone who experiences sudden vision loss while taking Wegovy should treat it as a medical emergency and contact their GP or go to A&E.

The MHRA continues to monitor the safety of GLP-1 medicines, and any new concern of this kind would appear in a Drug Safety Update, you can report suspected side effects via the Yellow Card scheme or check the MHRA's published communications for the latest position.

Why rapid weight loss itself can matter for eye pressure

This is the piece of the puzzle that surprises many people. Significant weight loss (through any route, not just GLP-1 medicines) can have indirect effects on fluid pressures in the body. For people who have idiopathic intracranial hypertension (IIH), a condition where cerebrospinal fluid pressure builds up and creates symptoms including headache and visual disturbance, weight loss is actually a primary treatment. That pressure reduction is beneficial in IIH, and some clinicians do use semaglutide in this context precisely because of the weight loss it produces. If you have noticed head pressure symptoms while taking the medication, our page on wegovy head pressure looks at why that can happen and when to seek advice.

For people with primary open-angle glaucoma, the picture is less studied. There is no established mechanism by which semaglutide raises intraocular pressure directly, but understanding the effect Wegovy can have on blood pressure is relevant here, since pressure changes associated with weight loss, shifts in fluid distribution, and systemic circulation may matter if your eyes are already vulnerable. Our overview of Wegovy and high blood pressure covers the systemic pressure side of this in more detail, since the two questions are sometimes connected in people managing multiple conditions.

If you already have glaucoma, raised intraocular pressure, or IIH, this is a conversation to have with your ophthalmologist before starting treatment, not after. Semaglutide is not contraindicated in these conditions, but your specialist and your prescriber need to be working from the same picture.

Diabetic retinopathy: the established, specific eye risk

There is one eye-related concern where the evidence is clearer. In people with type 2 diabetes who already have retinopathy, rapid blood sugar reduction (which semaglutide can cause) has been associated with a transient worsening of diabetic retinopathy in some cases. This effect is documented in the semaglutide prescribing information and is a reason why people with pre-existing retinopathy need a frank clinical assessment before starting or increasing their dose. People often ask whether any of these cardiovascular and circulatory effects are a cause for concern, and our page looking at whether Wegovy helps blood pressure addresses that broader question directly.

Wegovy is a prescription-only medicine and every person who starts it through a consultation with our prescribers goes through exactly this kind of assessment. A prescriber needs to know your full history, not just your BMI. That means disclosing any existing eye condition, any diabetic complications, and any relevant family history. The consultation is where these details shape the decision, not a checklist that happens after the fact.

You can read more about how semaglutide works and what the clinical programme found at our Wegovy overview page, or explore the broader range of licensed treatments at our weight-loss treatment hub.

When to get medical help, and what this means for your decision

It is completely understandable to feel uncertain here. You've read something, perhaps a news story about a study, and now you're weighing whether the concern applies to you. That's a reasonable response, not an overreaction.

The practical guidance is straightforward. Seek urgent help (same day, not next appointment) if you experience sudden blurred vision, loss of vision in part of your visual field, or eye pain. These are not symptoms to monitor at home. For slower-developing concerns, such as mild visual changes you're not sure about, book a review with your GP or optometrist and mention that you are taking semaglutide. Optometrists can measure intraocular pressure routinely; if it hasn't been checked in a while and you have risk factors, an eye test is the right first step. It is also worth reviewing our guidance on Wegovy and blood pressure, as changes in circulation are part of the wider picture your clinician will want to consider.

For anyone already managing glaucoma, IIH, or diabetic eye disease, the question isn't whether to raise this with a clinician, it's which clinician to start with. Your ophthalmologist can give an informed opinion on how weight-loss treatment might interact with your existing condition; your prescriber can then factor that into the clinical decision.

If you have questions about how our prescribers handle complex medical histories, you can read about how our service works or get in touch with our team directly. The FAQs page also covers common questions about the consultation process.